Monte Rosa Therapeutics reported revenue of $8.97M and net income of -$43.82M for the quarter ended Jun 2026, down 93.6% year over year. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 1.06M | 4.70M | 9.22M | 60.65M | 84.93M | 140.20M | 12.77M | 2.78M | 4.21M | 8.97M | |||||||||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 15.12M | 18.13M | 17.91M | 20.94M | 21.34M | 24.87M | 26.75M | 29.08M | 28.31M | 27.14M | 27.03M | 28.05M | 27.62M | 38.87M | 32.19M | 30.65M | 36.68M | 41.98M | 44.07M | 47.96M | |||||
| Selling, General & AdministrativeSG&A | 4.75M | 5.26M | 6.39M | 6.29M | 7.02M | 7.62M | 7.50M | 8.14M | 8.66M | 7.73M | 8.98M | 9.28M | 8.13M | 8.78M | 8.70M | 8.10M | 9.06M | 10.52M | 10.18M | 10.13M | |||||
| Restructuring CostsRestructuring | 6.81M | 7.62M | 7.46M | 7.75M | 8.23M | 7.85M | 8.57M | 9.21M | 10.11M | ||||||||||||||||
| Other Operating ExpensesOther Opex | 0.12M | -0.02M | 0.02M | 0.06M | |||||||||||||||||||||
| Operating ExpensesOpex | 19.87M | 23.39M | 24.30M | 27.23M | 28.36M | 32.49M | 34.26M | 37.22M | 36.97M | 34.86M | 36.01M | 37.34M | 35.74M | 47.64M | 40.89M | 38.75M | 45.74M | 52.50M | 54.24M | 58.10M | |||||
| Operating IncomeOp. Inc | -19.87M | -23.39M | -24.30M | -27.23M | -28.36M | -32.49M | -34.26M | -37.22M | -36.97M | -34.86M | -34.95M | -32.64M | -26.53M | 13.00M | 44.04M | -15.55M | -32.98M | -49.72M | -50.03M | -49.13M | |||||
| EBIT | -19.87M | -23.39M | -24.30M | -27.23M | -28.36M | -32.49M | -34.26M | -37.22M | -36.97M | -34.86M | -34.95M | -32.64M | -26.53M | 13.00M | 44.04M | -15.55M | -32.98M | -49.72M | -50.03M | -49.13M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | -0.13M | ||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.01M | 0.15M | 0.63M | 1.00M | 1.99M | 2.44M | 2.30M | 2.23M | 2.37M | 2.44M | 2.64M | 2.89M | 2.60M | 3.44M | 3.07M | 2.75M | 3.69M | 5.59M | 5.92M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | -0.07M | 0.10M | 0.13M | 0.06M | -0.28M | -0.09M | -0.09M | 0.03M | -0.78M | 0.62M | -0.05M | -0.15M | -3.07M | -0.05M | 1.39M | -0.03M | -3.39M | -0.06M | -0.05M | |||||
| Non Operating IncomeNon Op. Inc. | 0.03M | -0.05M | 0.37M | 0.76M | 1.04M | 1.71M | 2.22M | 2.23M | 2.25M | 1.59M | 3.06M | 2.58M | 2.74M | 2.60M | 3.67M | 4.46M | 2.72M | 3.64M | 5.58M | 5.94M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -19.86M | -23.37M | -24.15M | -26.47M | -27.32M | -30.78M | -32.04M | -34.99M | -34.71M | -33.27M | -31.89M | -30.06M | -23.79M | 15.60M | 47.71M | -11.10M | -30.26M | -46.08M | -44.45M | -43.19M | |||||
| Tax ProvisionsTaxes | 0.19M | 0.17M | -0.02M | 0.10M | 0.25M | 0.07M | -15.13M | 0.82M | 1.20M | -3.18M | -7.15M | 0.10M | 0.21M | ||||||||||||
| Profit After TaxPAT | -20.37M | -22.59M | -23.93M | -26.47M | -27.46M | -30.20M | -32.04M | -35.18M | -34.88M | -34.22M | -31.97M | -30.31M | -23.86M | 12.80M | 46.88M | -12.34M | -27.08M | -46.22M | -44.50M | -43.82M | |||||
| Income from Continuing OperationsIncome (Continuing) | -19.86M | -23.37M | -24.15M | -26.47M | -27.32M | -30.78M | -32.04M | -35.18M | -34.88M | -33.25M | -31.98M | -30.31M | -23.86M | 30.73M | 46.88M | -12.29M | -27.08M | -38.92M | -44.55M | -43.40M | |||||
| Consolidated Net IncomeConsol Net Inc. | -19.86M | -23.37M | -24.15M | -26.47M | -27.32M | -30.78M | -32.04M | -35.18M | -34.88M | -33.25M | -31.98M | -30.31M | -23.86M | 30.73M | 46.88M | -12.29M | -27.08M | -38.92M | -44.55M | -43.40M | |||||
| Income towards Parent CompanyParent Net Inc | -19.86M | -23.37M | -24.15M | -26.47M | -27.32M | -30.78M | -32.04M | -35.18M | -34.88M | -33.25M | -31.98M | -30.31M | -23.86M | 30.73M | 46.88M | -12.29M | -27.08M | -38.92M | -44.55M | -43.40M | |||||
| Net Income towards Common StockholdersNet Income | -19.86M | -23.37M | -24.15M | -26.47M | -27.32M | -30.78M | -32.04M | -35.18M | -34.88M | -33.25M | -31.98M | -30.31M | -23.86M | 30.73M | 46.88M | -12.29M | -27.08M | -38.92M | -44.55M | -43.40M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.43 | -0.93 | -0.52 | -0.57 | -0.58 | -0.65 | -0.65 | -0.71 | -0.70 | -0.65 | -0.53 | -0.43 | -0.29 | 0.42 | 0.57 | -0.15 | -0.33 | -0.47 | -0.45 | -0.43 | |||||
| EPS (Diluted) | -0.43 | -0.93 | -0.52 | -0.57 | -0.58 | -0.65 | -0.65 | -0.71 | -0.70 | -0.65 | -0.53 | -0.43 | -0.29 | 0.42 | 0.57 | -0.15 | -0.33 | -0.47 | -0.45 | -0.43 | |||||
| Shares Outstanding | 45.99M | 25.00M | 46.60M | 46.67M | 46.73M | 47.23M | 49.35M | 49.43M | 49.81M | 51.40M | 60.16M | 71.23M | 82.01M | 73.91M | 82.15M | 82.19M | 82.40M | 83.07M | 99.88M | 101.48M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 45.99M | 25.00M | 46.60M | 46.67M | 46.73M | 47.23M | 49.35M | 49.43M | 49.81M | 51.40M | 60.16M | 71.23M | 82.01M | 73.91M | 82.96M | 82.19M | 82.40M | 83.07M | 99.88M | 101.48M | |||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 46.48M | 25.00M | 46.63M | 46.68M | 48.37M | 49.32M | 49.36M | 49.59M | 50.07M | 50.14M | 50.20M | 61.33M | 82.01M | 61.51M | 82.15M | 82.19M | 82.40M | 83.07M | 84.32M | 85.23M | |||||
| EBITDA | -19.87M | -23.39M | -24.30M | -27.23M | -28.36M | -32.49M | -34.26M | -37.22M | -36.97M | -34.86M | -34.95M | -32.64M | -26.53M | 13.00M | 44.04M | -15.55M | -32.98M | -49.72M | -50.03M | -49.13M | |||||
| Tax Rate | -0.54% | -0.49% | 0.07% | -0.31% | -0.84% | -0.30% | -97.00% | 1.72% | -10.81% | 10.50% | 15.52% | -0.22% | -0.48% |